GC4419 (avasopasem manganese)
GTI-4419-203
Phase 2 small_molecule terminated
Quick answer
GC4419 (avasopasem manganese) for Esophagitis is a Phase 2 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Galera Therapeutics
- Indication
- Esophagitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated